Effects of cannabinoid receptor‐2 activation on accelerated gastrointestinal transit in lipopolysaccharide‐treated rats
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The biological effects of cannabinoids (CB) are mediated by CB 1 and CB 2 receptors. The role of CB 2 receptors in the gastrointestinal tract is uncertain. In this study, we examined whether CB 2 receptor activation is involved in the regulation of gastrointestinal transit in rats. Basal and lipopolysaccharide (LPS)‐stimulated gastrointestinal transit was measured after instillation of an Evans blue‐gum Arabic suspension into the stomach, in the presence of specific CB 1 and CB 2 agonists and antagonists, or after treatment with inhibitors of mediators implicated in the transit process. In control rats a CB 1 (ACEA; 1 mg kg−1), but not a CB 2 (JWH‐133; 1 mg kg−1), receptor agonist inhibited basal gastrointestinal transit. The effects of the CB 1 agonist were reversed by the CB 1 antagonist AM‐251, which alone increased basal transit. LPS treatment increased gastrointestinal transit. This increased transit was reduced to control values by the CB 2, but not the CB 1, agonist. This inhibition by the CB 2 agonist was dose dependent and prevented by a selective CB 2 antagonist (AM‐630; 1 mg kg−1). By evaluating the inhibition of LPS‐enhanced gastrointestinal transit by different antagonists, the effects of the CB 2 agonist (JWH‐133; 1 mg kg−1) were found to act via cyclooxygenase, and to act independently of inducible nitric oxide synthase (NOS) and platelet‐activating factor. Interleukin‐1 β and constitutive NOS isoforms may be involved in the accelerated LPS transit. The activation of CB 2 receptors in response to LPS is a mechanism for the re‐establishment of normal gastrointestinal transit after an inflammatory stimulus. British Journal of Pharmacology (2004) 142, 1247–1254. doi:10.1038/sj.bjp.0705889
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“…cannabinoid receptor ligands (Herkenham et al., 1990; Palmer et al., 2002; Pertwee & Ross, 2002), the identification of endogenous cannabinoids (Devane et al., 1992), and the isolation of a cannabinoid receptor from brain (Matsuda et al., 1990) and another one from the spleen (Munro et al., 1993).”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 1×
“Cannabinoid research has evolved rapidly over the last decade with the development of specific cannabinoid receptor ligands (Herkenham et al., 1990; Palmer et al., 2002; Pertwee & Ross, 2002), the identification of endogenous cannabinoids (Devane et al., 1992), and the isolation of a cannabinoid…”
BackgroundINTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology
Arend, W. P., Malyak, M., Guthridge, C. J., & Gabay, C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.27 · Cited by 1,071
Gatley, S. J., Gifford, A. N., Volkow, N. D., Lan, R., & Makriyannis, A. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00279-8 · Cited by 252 · cited 1×
“…(ACEA; Hillard et al., 1999); CB1 antagonist – N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM-251; Gatley et al., 1996); CB2 agonist – (6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d] pyran (JWH-133;…”
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Future studies should further explore the mechanisms of the anti-inflammatory effects of cannabinoids and the potential role of CB2 receptors as therapeutic targets (Mathison et al., 2004; Wright et al., 2005).”
BackgroundCannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
“Also, activation of CB 2 was recently shown to attenuate LPS-induced increases in gastrointestinal transi”
BackgroundCB2: a cannabinoid receptor with an identity crisis
Atwood, B. K., & Mackie, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00729.x · Cited by 619
Cannabinoids and the gut: New developments and emerging concepts
Izzo, A. A., & Sharkey, K. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.005 · Cited by 419
Self-citationCannabinoid Hyperemesis Syndrome
A. Galli, J., Andari Sawaya, R., & K. Friedenberg, F. (2011) · Current Drug Abuse Reviewse · doi:10.2174/1874473711104040241 · Cited by 303
Metadata
- Authors
- Mathison, R., Ho, W., Pittman, Q. J., Davison, J. S., & Sharkey, K. A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2004-08
- Volume
- 142
- Issue
- 8
- Pages
- 1247-1254
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1999383205
- Cited by
- 141
- References
- 6
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.